# Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

> **NCT06160206** · PHASE2 · RECRUITING · sponsor: **Academic and Community Cancer Research United** · enrollment: 134 (estimated)

## Conditions studied

- Recurrent Glioblastoma
- Recurrent WHO Grade 4 Glioma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **OTHER:** Electronic Health Record Review
- **RADIATION:** Hypofractionated Radiation Therapy
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Retifanlimab

## Key facts

- **NCT ID:** NCT06160206
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-02
- **Primary completion:** 2026-11-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06160206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06160206, "Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06160206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*